Vac17p Inhibitors
Vac17p Inhibitors predominantly target vesicle trafficking and the cytoskeletal dynamics, providing a pathway-centric avenue to indirectly modulate the activity or function of Vac17p. One of the notable features of these chemicals is their interference with pivotal cellular processes. For instance, Wortmannin and LY294002 target PI3K, a linchpin in various cellular pathways including vesicle trafficking. Similarly, Dynasore, which inhibits the GTPase activity of dynamin, has profound effects on vesicle scission, a step integral to vesicle formation and transport.
Another avenue that these inhibitors employ to potentially regulate Vac17p-associated processes is by modulating the cellular cytoskeleton. Compounds like Nocodazole and Cytochalasin D interfere with the dynamics of microtubules and actin filaments, respectively. Given the significance of the cytoskeleton in vesicle transport, it's plausible that altering its dynamics can indirectly affect proteins involved in the vesicle transport machinery, such as Vac17p.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, which can affect vesicle trafficking pathways that Vac17p might be involved in. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Targets the GTPase activity of dynamin, potentially affecting vesicle scission and related pathways. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts the structure and function of the Golgi apparatus, which might affect vesicle transport. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Depolymerizes microtubules, potentially affecting vesicle movement mechanisms that involve Vac17p. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Inhibits actin polymerization which can affect cytoskeleton-dependent processes. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Tyrosine kinase inhibitor that might affect signaling processes related to vesicle transport. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Binds actin monomers and prevents polymerization, affecting actin dynamics and related processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Rho-associated protein kinase (ROCK) inhibitor, potentially affecting cytoskeleton dynamics. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase, potentially affecting vesicle transport reliant on myosin. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Farnesyltransferase inhibitor, affecting protein prenylation and potentially vesicle associated proteins. | ||||||